ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1800

Safety and Humoral Immunogenicity to Herpes Zoster Vaccine in Patients with Rheumatoid Arthritis (interim Analysis)

Ori Elkayam1, Itzhak Rosner 2, Devy Zisman 3, Merav Lidar 4, Reuven Mader 5, Amir Bieber 5, Alexandra Balbir-Gurman 6, Mirit Amit 7, Smadar Gertel 8 and Victoria Furer 9, 1Rheumatology Department, Tel Aviv Medical Center, and Sackler Faculty of Medicine, Tel Aviv University, Israel., Tel Aviv, Israel, 2Bnei Tzion, Haifa, Israel, 3Carmel Hospital and Ruth and Bruce Rappaport Faculty of Medicine, Technion, Israel, Haifa, Israel, 4Sheba Medical Center, Ramat Gan, Israel, 5Ha emek medical center, Afula, Israel, 6Rambam Medical Center, Haifa, Israel, 7Shamir medical center, Zerifin, Israel, 8Tel Aviv medical center, Tel Aviv, Israel, 9Sourasky Medical Center, Tel-Aviv, Israel

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: rheumatoid arthritis (RA) and infection, Vaccines

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 11, 2019

Session Title: 4M090: Infection-Related Rheumatic Disease (1800–1805)

Session Type: ACR Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose: To evaluate the safety and humoral immunogenicity of   a live attenuated herpes zoster (HZ) vaccine in patients with rheumatoid arthritis (RA) compared with healthy controls (HC).

Methods: This is a prospective multicenter study of a live attenuated HZ vaccine in 132 patients with RA receiving conventional disease-modifying anti rheumatic drugs (cDMARD) and/or low-dose glucocorticoids (GC), candidates to receive biologics or tofacitinib. The control groups was composed of 35 HC. All the subjects, above the age of 50 years. Clinical and laboratory assessments were performed at baseline and after 6 weeks. Each assessment included RA disease activity score (DAS-28) for RA patients, recording of side effects and blood samples for the evaluation of immunogenicity for each subject. At week 2 and 4 after vaccination, patients were contacted by phone and asked for adverse events. The immunogenicity was assessed using varicella zoster virus (VZV)-specific ELISA (Serion)  

Results: 132 RA patients (median age   66, range 50-89, 81% women) and 35 HC (median age 67, range 51-100, 69 % women) were vaccinated with the Zostavax (MSD) vaccine. Safety:  67 (52%) of the RA patients and 12 (32%) of the HC developed vaccine related side effects. In the HC, all were local reactions to the vaccine which resolved after a few days. In the RA group, the adverse events included: 56 local reactions, 11 systemic reactions such as fever, 2 mild rash, and 1 event of herpes zoster. Seven RA patients reported worsening of the RA  Effect on disease activity :No change in disease activity was observed . DAS28-ESR at baseline was (median [min, max], n (out of 132)) (4 [2,8], n=126/132) and (4, [1,9], n=121/132) after 6 weeks. Immunogenicity: The number of patients with non-protective titer at baseline was 1 (RA=0, and controls=1). The titer increased from (median [min, max], n) (877 [101, 3153], n=129/132) to (1327 [99, 4836], n=126) for RA and from (962 [54, 1650], n=35) to (1533 [222, 3564]) in the control group. The increase in each group was statistically significant (pv< 0.0001 for both groups, Wilcoxon signed-rank test, n.RA=124, n.Control=35). The degree of humoral response was similar in the 2 groups (p=0.238, Mann-Whitney Test, n.RA=124, n.Control=35)

Conclusion: In RA patients treated with cDMARDs, vaccination with a live attenuated vaccine against herpes zoster was safe and induced an adequate booster response


Disclosure: O. Elkayam, Pfizer, 2, 5, 8; I. Rosner, None; D. Zisman, Pfizer, 5, 8; M. Lidar, Pfizer, 5, 8; R. Mader, None; A. Bieber, None; A. Balbir-Gurman, Pfizer, 5, 8; M. Amit, None; S. Gertel, None; V. Furer, None.

To cite this abstract in AMA style:

Elkayam O, Rosner I, Zisman D, Lidar M, Mader R, Bieber A, Balbir-Gurman A, Amit M, Gertel S, Furer V. Safety and Humoral Immunogenicity to Herpes Zoster Vaccine in Patients with Rheumatoid Arthritis (interim Analysis) [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/safety-and-humoral-immunogenicity-to-herpes-zoster-vaccine-in-patients-with-rheumatoid-arthritis-interim-analysis/. Accessed January 30, 2023.
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/safety-and-humoral-immunogenicity-to-herpes-zoster-vaccine-in-patients-with-rheumatoid-arthritis-interim-analysis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences